Breaking News, Collaborations & Alliances

Caladrius, Cognate Ink Clinical Manufacturing Agreement

For phase 3 trial of CLBS14 in no-option refractory disabling angina

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Caladrius Biosciences and Cognate BioServices, a contract development and manufacturing organization (CDMO) in the global cellular therapies industry, have entered into a manufacturing agreement for the production of CLBS14, Caladrius’ CD34+ cell therapy. Cognate will manufacture CLBS14 for Caladrius’ Phase 3 confirmatory pivotal clinical trial in subjects with no-option refractory disabling angina (NORDA).   “Selecting the right company for the manufacturing and supply of CLBS14 is critical to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters